金融界9月30日消息，东阳光长江药业发布了2024年中期报告，该报告显示，公司在2024年上半年的营业额为2,454,762千元，毛利为1,949,232千元。公司的营业利润为867,385千元，税前利润为813,531千元。公司的总资产为12,494,196千元，总负债为3,828,816千元，净资产为8,665,380千元。此外，报告显示，公司的毛利率为79.4%，营业利润率为35.3%，净利润率为27.9%。以上数据未经审核。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.